Reconsidering Lacrisert: An Overlooked Opportunity to Manage Moderate to Severe Dry Eye Disease

Highlights of A Roundtable Discussion

Although LACRISERT, a unique, preservative-free, slow-release artificial tear, has been available for decades and is a central part of many patients’ moderate to severe DED treatment regimens, younger patients and practitioners may be unaware of it. This supplement presents the perspectives and clinical experiences of a panel of experts on the opportunity LACRISERT presents for treating moderate to severe DED. 

Sponsored by Bausch + Lomb.